Navifus Corporation
NaviFUS is a company specializing in transcranial focused ultrasound (FUS) technology, with a mission to develop safe and effective FUS solutions for treating central nervous system (CNS) diseases, including brain tumors, epilepsy, Alzheimer's disease, and other neurological conditions. The company aims to provide non-invasive, precise, and accessible treatments to improve patient outcomes worldwide.
Industries
Nr. of Employees
small (1-50)
Navifus Corporation
Products
Neuronavigation‑guided transcranial focused ultrasound platform
Standalone transcranial focused ultrasound platform that uses optical neuronavigation and pre‑treatment CT/MR planning to non‑invasively focus ultrasound to targeted brain regions for BBB opening and neuromodulation; incorporates phased‑array transducer, acoustic emission feedback, and passive acoustic imaging for targeting verification.
3D image‑guided needle‑tracking system for RFA
Needle‑tracking system combining ultrasound imaging, optical tracking and image‑analysis algorithms to display real‑time needle‑tip location for radiofrequency ablation procedures, intended to improve accuracy and reduce repeated imaging checks.
Neuronavigation‑guided transcranial focused ultrasound platform
Standalone transcranial focused ultrasound platform that uses optical neuronavigation and pre‑treatment CT/MR planning to non‑invasively focus ultrasound to targeted brain regions for BBB opening and neuromodulation; incorporates phased‑array transducer, acoustic emission feedback, and passive acoustic imaging for targeting verification.
3D image‑guided needle‑tracking system for RFA
Needle‑tracking system combining ultrasound imaging, optical tracking and image‑analysis algorithms to display real‑time needle‑tip location for radiofrequency ablation procedures, intended to improve accuracy and reduce repeated imaging checks.
Services
Design and operational support for first‑in‑human and early‑phase clinical studies using neuronavigation‑guided focused ultrasound, including procedural workflow, safety monitoring with acoustic feedback, and imaging endpoints.
Provision of research‑configured focused ultrasound systems for academic and translational studies on BBB opening, neuromodulation, and drug‑delivery experiments, with support for multi‑modal endpoints such as imaging and electrophysiology.
Design and operational support for first‑in‑human and early‑phase clinical studies using neuronavigation‑guided focused ultrasound, including procedural workflow, safety monitoring with acoustic feedback, and imaging endpoints.
Provision of research‑configured focused ultrasound systems for academic and translational studies on BBB opening, neuromodulation, and drug‑delivery experiments, with support for multi‑modal endpoints such as imaging and electrophysiology.
Expertise Areas
- Focused ultrasound for central nervous system therapy
- Transcranial blood–brain barrier modulation
- Neuromodulation and seizure‑prevention modalities
- Image‑guided interventional systems and neuronavigation
Key Technologies
- Transcranial focused ultrasound
- Low‑intensity focused ultrasound (LIFU)
- Microbubble‑enhanced ultrasound delivery
- Phased‑array ultrasound transducers with electronic beam steering
News & Updates
NaviFUS received approval to begin human clinical trials for Alzheimer’s Disease treatment in Australia, evaluating safety and efficacy.
The company has conducted clinical trials in Taiwan for recurrent glioblastoma and drug-resistant epilepsy, demonstrating safety and potential efficacy.
The NaviFUS Focused Ultrasound System was awarded Gold at the 2022 Edison Awards for innovation in outpatient treatment.
An article discussing how focused ultrasound technology is revolutionizing medical treatments, including cancer therapy and CNS disease management.
Overview of NaviFUS's clinical trials, technological innovations, and regulatory milestones in developing non-invasive treatments for brain diseases.
NaviFUS was shortlisted as a finalist for the 2022 Edison Awards in the Science & Medical Outpatient Treatment category, recognizing its innovative focused ultrasound platform.
NaviFUS received approval to begin human clinical trials for Alzheimer’s Disease treatment in Australia, evaluating safety and efficacy.
The company has conducted clinical trials in Taiwan for recurrent glioblastoma and drug-resistant epilepsy, demonstrating safety and potential efficacy.
The NaviFUS Focused Ultrasound System was awarded Gold at the 2022 Edison Awards for innovation in outpatient treatment.
An article discussing how focused ultrasound technology is revolutionizing medical treatments, including cancer therapy and CNS disease management.
Overview of NaviFUS's clinical trials, technological innovations, and regulatory milestones in developing non-invasive treatments for brain diseases.
NaviFUS was shortlisted as a finalist for the 2022 Edison Awards in the Science & Medical Outpatient Treatment category, recognizing its innovative focused ultrasound platform.